Baxter (NYSE:BAX) this week received a grand jury subpoena from the Antitrust Division of the US Department of Justice related to a criminal investigation, the company said in an SEC filing posted this week.
The subpoena from US District Court for the Eastern District of Pennsylvania calls for the company to submit documents and testimony related to the manufacturing, selling, pricing and shortages of intravenous solutions and containers, including saline solutions and other injectable medicines.
Baxter said the form also requests the company disclose all communications with competitors regarding the same, according to an SEC filing.
The Deerfield, Ill.-based company said it is cooperating with the US Department of Justice on the investigation, and added that prior to this request, the New York Attorney General’s office had requested information about business practices related to its IV saline industry.
In February, Baxter said it received a civil investigative demand from the US Dept. of Justice’s Commercial Litigation Branch related to its Tisseel and Artiss products.
The company said the inquiry relates to contingent discount arrangements and other promotions for the 2 sealant products, and that it was cooperating with the DoJ on the matter.
Baxter said it also resolved an investigative matter initiated in 2012 by the US Attorney for the Western District of North Carolina relating to quality and manufacturing practices at its North Cove facility.